Hypothesis
Integrating bone turnover biomarkers (CTX and P1NP) with FRAX risk stratification and rheumatological context produces superior therapeutic selection for osteoporosis compared to FRAX alone.
Background
FRAX estimates 10-year fracture probability but provides no guidance on which therapy to use. Current guidelines recommend "clinical judgment" without a structured algorithm integrating biochemical markers of bone remodeling. This gap is particularly problematic in rheumatology, where glucocorticoid dose (not binary), disease activity, and immunomodulatory therapies significantly modify bone metabolism in ways FRAX ignores.
The OSTEO-TX Algorithm
We propose a 4-step expert system:
Step 1 — Baseline Correction: Mandatory correction of vitamin D deficiency (<20 ng/mL) and calcium abnormalities before therapeutic selection.
Rationale: antiresorptives in hypocalcemia cause dangerous complications.





























